ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative) |
Aug. 19, 2019
USD ($)
|
|---|---|
| Asset Purchase Agreement [Member] | TRImaran Pharma Inc [Member] | |
| Asset Acquisition [Line Items] | |
| Payment for purchase of assets | $ 100,000 |
| Liabilities assumed | 68,500 |
| Research and development costs | 168,500 |
| Contingent milestone payment obligation | 3,400,000 |
| WSU License Agreement [Member] | |
| Asset Acquisition [Line Items] | |
| Reimbursement of patent expenses | 75,000 |
| Contingent milestone payment obligation | $ 3,400,000 |
| Percentage of royalties payable to any third party for intellectual property rights | 50.00% |
| Maximum percentage reduction of royalties payable | 50.00% |
| X | ||||||||||
- Definition The amount upon the achievement of specified development, regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Tonix's option per agreement. No definition available.
|
| X | ||||||||||
- Definition The amount of obligation to make contingent milestone payments. No definition available.
|
| X | ||||||||||
- Definition The maximum percentage by which royalties payable may be reduced. No definition available.
|
| X | ||||||||||
- Definition The percentage of royalties payable to any third party for intellectual property rights which are necessary for the practice of the rights licensed which may reduce royalties payable on net sales. No definition available.
|
| X | ||||||||||
- Definition The amount paid for reimbursement of patent expenses. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|